HyperfineHYPR -12.76%78 Days Payable is 204.01 as of Mar. 2026, which is 69% above its 10-year median of 121.02. GuruFocus rates HYPR with a GF Score™ of 78/100 and a GF Value™ of $1.31 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Hyperfine ranks better than 81.16% on this metric.
Hyperfine's average Accounts Payable for the
three
months ended in Mar. 2026 was $4.30 Mil. Hyperfine's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.92 Mil.
Hence, Hyperfine's Days Payable for the
three
months ended in Mar. 2026 was 204.01.
The historical rank and industry rank for Hyperfine's Days Payable or its related term are showing as below:
HYPR'
s Days Payable Range Over the Past 10 Years
Min: 55.03 Med: 121.02 Max: 505.84
Current: 171.66
During the past 7 years, Hyperfine's highest Days Payable was 505.84. The lowest was 55.03. And the median was 121.02.
HYPR's Days Payable is ranked better than 81.16% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs HYPR: 171.66
Hyperfine's Days Payable
increased
from Mar. 2025 (142.33) to Mar. 2026 (204.01).
It may suggest that Hyperfinedelayed paying its suppliers.
Hyperfine Days Payable Related Terms
Hyperfine Days Payable Historical Data
* Premium members only.
The historical data trend for Hyperfine's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Hyperfine's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyperfine Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hyperfine's Days Payable distribution charts can be found below:
* The bar in red indicates where Hyperfine's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hyperfine's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyperfine (HYPR) has a Days Payable of 204.01 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hyperfine and its competitors. This is 69% above median its historical median of 121.02. Over the past decade, Hyperfine's Days Payable has ranged from 55.03 to 505.84. According to the industry distribution chart, Hyperfine ranks #150 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 18.8%.
Is Hyperfine's Days Payable too high?
Hyperfine's current Days Payable of 204.01 is 69% above median its 10-year median of 121.02. Over the past 10 years, this metric has ranged from a low of 55.03 to a high of 505.84. The Medical Devices & Instruments industry median Days Payable is 68.14. Hyperfine's value of 204.01 is 199.4% above this industry median. Based on the distribution chart, Hyperfine ranks #150 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hyperfine has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyperfine's Days Payable compare to OWLT and CVRX?
According to the Medical Devices & Instruments industry distribution chart, Hyperfine ranks #150 out of 796 companies for Days Payable. This places Hyperfine in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.14. Hyperfine's value of 204.01 is 199.4% above this benchmark. Historically, Hyperfine's own Days Payable has ranged from 55.03 to 505.84 over the past decade. While the company's 10-year median is 121.02 vs. the industry median of 68.14, Hyperfine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyperfine's current Days Payable of 204.01 is 199.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hyperfine and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyperfine's current Days Payable is 204.01, which is 69% above median its own 10-year median of 121.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyperfine stock overvalued right now?
Based on GuruFocus' analysis, Hyperfine (HYPR) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.31, compared to a current price of $1.47 — trading 12.2% above its estimated fair value. The current Days Payable is 204.01, which is 69% above median its 10-year median of 121.02 and 199.4% above the Medical Devices & Instruments industry median of 68.14. Hyperfine's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hyperfine (HYPR), the current Days Payable is 204.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyperfine (HYPR) Overvalued in 2026?
Based on GuruFocus' analysis, Hyperfine stock appears to be overvalued.
The current stock price of $1.47 is trading 12.2% above its estimated GF Value™ of $1.31.
GuruFocus considers Hyperfine to be Modestly Overvalued.
Key valuation signals for HYPR:
Days Payable: 204.01 (69% above median its 10-year median of 121.02)
GF Value™: $1.31 vs. price of $1.47 (12.2% above fair value)
Industry Position: 199.4% above the Medical Devices & Instruments median (#150 of 796)
No single metric tells the full story. See the HYPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
78GF Score
Get the complete analysis for HYPR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYPR has been successfully added to your 
